Community Practice Connections™: Exploring Future Applications of HER2/3-Targeted Therapies Across Multiple Tumor Types

Release Date: August 31, 2020
Expiration Date: August 31, 2021

Activity Overview

For over 20 years, trastuzumab has been the foundation of therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Within the past 6 months, several new HER2-targeted therapies have been approved and are available for continual improvement of treatment outcomes for these patients. HER2 and HER3 amplification have been increasingly recognized as a frequent abnormality in not only gastric cancer, but also gastroesophageal and colorectal cancers, enabling oncologists to administer HER2/3-targeted therapies to these patients as well. While EGFR, another receptor related to HER2, has long been a target successfully treated in patients with non–small cell lung cancer, novel anti-HER2 agents have emerged to combat tumor resistance.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the live satellite symposium presented at the 2020 ASCO Annual Meeting held in May 2020. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with HER2-positive advanced cancer, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgment of Commercial Support.

Target Audience

This educational activity is directed toward medical oncologists, pathologists, radiation oncologists, and surgical oncologists interested in the treatment of cancer. Fellows, nurse practitioners, nurses, physician assistants, researchers, and other health care professionals interested in the treatment of breast, lung, and gastrointestinal cancers are also welcome to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Discuss the rationale supporting the role of HER2/3-targeted therapies across multiple tumor types
• Outline HER2 testing strategies across multiple tumor types
• Review recent clinical trial data and ongoing clinical trials evaluating HER2/3-targeted strategies across multiple cancers
• Discuss strategies for integrating HER2/3-targeted therapies into clinical practice for the treatment of multiple tumor types, including mitigation of treatment-associated adverse events

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Program Chair

Sara A. Hurvitz, MD, Program Chair
Associate Professor of Medicine, Division of Hematology/Oncology
Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica-UCLA Outpatient Hematology/Oncology Practice
David Geffen School of Medicine at UCLA
Santa Monica, CA

 

Disclosures: Grant Research Support: Research support to institution: Ambrx Inc, Amgen Inc, Arvinas Inc, Bayer AG, Daiichi Sankyo Inc, Dignitana AB, Genentech Inc/F. Hoffman-La Roche Ltd, GlaxoSmithKline plc, Immunomedics Inc, MacroGenics Inc, Novartis AG, OBI Pharma Inc, Pfizer Inc, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Sanofi SA, Seattle Genetics Inc; Consultant: NKMax America Inc; Other: Travel: Eli Lilly and Company

Hossein Borghaei, DO, MS
Professor and Chief, Thoracic Medical Oncology
The Gloria and Edmund M. Dunn Chair in Thoracic Surgical Oncology
Fox Chase Cancer Center
Philadelphia, PA

Disclosures: Grant Research Support: Bristol Myers Squibb Company/Eli Lilly and Company, Merck & Co, Inc/Celgene Corporation, Millennium Pharmaceuticals Inc; Consultant: AbbVie Inc, Amgen Inc, AstraZeneca, Axiom, Boehringer Ingelheim International GmbH, BioNTech SE, Bristol Myers Squibb Company, Cantargia AB, Celgene Corporation, Daiichi Sankyo Company Ltd, EMD Serono Inc, Genentech Inc, Genmab A/S, GLG Pharma Inc, HUYA Bioscience International, Eli Lilly and Company, Merck & Co Inc, Novartis AG, Pfizer Inc, PharmaMar SA, Regeneron Pharmaceuticals Inc, Takeda Pharmaceutical Company Ltd; Speakers Bureau: Sonnet BioTherapeutics Inc, Rgenix Inc (scientific advisory board); Other: Data and safety monitoring board: University of Pennsylvania, CAR T program, Incyte Corporation, Takeda Pharmaceutical Company Ltd.

Ian Krop, MD, PhD
Associate Chief, Division of Breast Oncology
Susan F. Smith Center for Women's Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant Research Support: Daiichi Sankyo Inc, Genentech Inc/F. Hoffman-La Roche Ltd, MacroGenics Inc, Pfizer Inc; Consultant: Bristol Myers Squibb Company, Context Therapeutics LLC, Daiichi Sankyo Inc, Genentech Inc/F. Hoffman-La Roche Ltd, MacroGenics Inc, Merck & Co Inc, Novartis AG, Taiho Oncology Inc.

Manish A. Shah, MD, FASCO
Chief, Solid Tumor Oncology Service
Director, Gastrointestinal Oncology Program
Codirector, Center for Advanced Digestive Disease
Bartlett Family Associate Professor of Gastrointestinal Oncology
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine and New York-Presbyterian Hospital
New York, NY

Disclosures: Grant Research Support: Astellas Pharma US Inc, Bristol Myers Squibb Company, Merck & Co Inc, Oncolys BioPharma Inc.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.